Trials / Completed
CompletedNCT05192200
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-Beta Interferon (PF-06823859) | IV infusion |
Timeline
- Start date
- 2021-12-20
- Primary completion
- 2023-11-20
- Completion
- 2023-11-20
- First posted
- 2022-01-14
- Last updated
- 2025-02-06
- Results posted
- 2025-02-06
Locations
25 sites across 4 countries: United States, Hungary, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05192200. Inclusion in this directory is not an endorsement.